+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse testis tissue lysate, Primary antibody: P04089(MAGEA2 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 30 seconds    

  
  

The MAGE-A2 antibody targets the melanoma-associated antigen A2 (MAGEA2), a member of the MAGE (melanoma antigen gene) family. MAGEA2 is part of the MAGE-A subfamily, which consists of cancer-testis antigens (CTAs) primarily expressed in germ cells (e.g., testes, placenta) but silenced in most healthy somatic tissues. Aberrant MAGEA2 expression is observed in various cancers, including melanoma, lung, liver, and head/neck carcinomas, making it a tumor-specific biomarker and therapeutic target. Its restricted normal tissue expression reduces off-target risks, enhancing its appeal for immunotherapy.

MAGEA2 antibodies are critical tools in research and diagnostics, used to detect protein expression via techniques like immunohistochemistry (IHC) or Western blotting. Clinically, MAGEA2 is explored for immunotherapeutic strategies, such as cancer vaccines, adoptive T-cell therapies, or antibody-drug conjugates (ADCs), aiming to direct immune responses or cytotoxic agents against MAGEA2-positive tumor cells. However, challenges persist, including heterogeneous MAGEA2 expression within tumors, potential immune evasion mechanisms, and safety concerns if expression occurs in immune-privileged sites. Despite these hurdles, MAGEA2 remains a promising candidate for precision oncology, with ongoing studies optimizing its targeting efficacy and specificity.